科特迪瓦晚期HIV患者组织胞浆菌抗原尿患病率:STATIS试验辅助研究
本研究为ANRS STATIS试验的辅助研究,分析科特迪瓦新诊断HIV且CD4+ T细胞<100/µL患者的尿液样本,组织胞浆菌抗原尿患病率为24.3%(68/280),其中无症状/有症状分布及与结核重叠情况已报告,死亡患者中患病率较高。
要点
- 晚期HIV患者组织胞浆菌抗原尿患病率为24.3%(95%CI 19.5%-29.8%)。
- 22例结核病例中8例(36.4%)同时有组织胞浆菌抗原尿。
- 48周内死亡者抗原尿患病率35.7%,存活者22.3%。
核心结论
- 组织胞浆菌抗原尿患病率与结核相当,组织胞浆菌病可能是可预防死亡的原因之一。
- 需要前瞻性研究确认这些发现并推广撒哈拉以南非洲的筛查策略。
研究设计与样本
- ANRS STATIS试验的辅助研究,分析科特迪瓦既往入组患者的尿液样本。
- 对象为新诊断HIV、CD4+ T细胞<100/µL且符合抗逆转录病毒治疗条件的门诊患者,随机接受系统或检测引导的结核治疗。
- 采用组织胞浆菌抗原酶免疫分析法检测尿液。
主要发现
- 组织胞浆菌抗原尿患病率为68/280(24.3%;95%CI 19.5%-29.8%)。
- 有症状患者中患病率为52/280(18.6%;95%CI 14.3%-23.7%)。
- 22例入组时确诊结核病例中,8例(36.4%)同时有组织胞浆菌抗原尿。
- 48周随访内死亡患者中抗原尿患病率为15/42(35.7%;95%CI 22.0%-52.0%),存活者为22.3%(95%CI 17.3%-28.2%)。
- 存活者体重指数、CD4+ T细胞计数、血红蛋白和血小板计数均高于死亡者。
临床怎么用
- 在晚期HIV患者中应考虑组织胞浆菌抗原尿筛查,因其患病率与结核相当。
- 对结核患者也应警惕合并组织胞浆菌病的可能。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite tuberculosis being a well-known concern in patients with advanced human immunodeficiency virus (HIV), the STATIS trial, which focused on its management, highlighted significant mortality rates. Histoplasmosis, a fungal disease endemic in sub-Saharan Africa, presents with similar clinical manifestations as tuberculosis. Therefore, it may be prevalent and potentially responsible for deaths in patients with advanced HIV in this region. We conducted an ancillary study of the ANRS STATIS trial to provide the first prevalence estimates of histoplasmosis among individuals with advanced HIV in Côte d'Ivoire. METHODS: We analyzed urine samples from patients previously enrolled in the STATIS trial in Côte d'Ivoire. These ambulatory patients with newly diagnosed HIV infection, CD4+ T-cell counts <100/µL, and eligible for antiretroviral therapy (ART) were randomized to receive either systematic or test-guided tuberculosis treatment. We performed Histoplasma antigen enzyme immunoassay on their urine samples. RESULTS: The prevalence of Histoplasma antigenuria was 68/280 (24.3%; 95% CI: 19.5%-29.8%), including 52/280 (18.6%; 95% CI: 14.3%-23.7%) symptomatic patients. Of 22 tuberculosis cases documented at inclusion, 8 (36.4%) also had Histoplasma antigenuria. In patients who died within the 48-week follow-up, the prevalence of Histoplasma antigenuria was 15/42 (35.7%% 95% CI: 22.0%-52.0%) compared with 22.3% (95% CI: 17.3%-28.2%) in those surviving. These survivors had a higher body mass index, CD4+ T-cell count, and hemoglobin and platelet count than those who died. CONCLUSIONS: The prevalence of Histoplasma antigenuria was comparable to that of tuberculosis, and histoplasmosis was potentially responsible for preventable deaths. Prospective studies are needed to confirm these findings and promote screening strategies in sub-Saharan Africa.
引用
- Sturny-Leclère A, Françoise U, Badjé AD, et al. Histoplasma Antigenuria Prevalence in Patients With Advanced HIV Disease in Côte d'Ivoire: A Prospective Trial Ancillary Study. Clin Infect Dis. 2025. PMID: 40377456. doi:10.1093/cid/ciaf237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。